上述重要的研究进展和成果先后荣获国家科技进步一等奖和二等奖各1项、中国药学科学技术一等奖1项、省部级科技奖励数十项，获得生物制品类国家Ⅰ类新药证书1项、检测试剂类国家Ⅰ类新药证书1项，获得国家发明专利近百项，在Nature Clinical Practice Oncology、Lancet和Hepatology等SCI收录杂志发表论文200余篇，取得了良好的经济效益和社会效益。
State Key Laboratory of Cancer Biology (Fourth Military Medical University)
The State Key Laboratory of Cancer Biology (CBSKL) is mainly comprised of the PLA Key Laboratory of Gastroenterology and PLA Key Laboratory of Molecular Biology, Cell Engineering Base of National 863 Project as well as Cancer Institute of the Fourth Military Medical University. The application for State Key Laboratory of Cancer Biology was initiated in June 2004, and Laboratory was temporarily approved to enter construction stage after investigation and demonstration by Ministry of Science and Technology of China in April 2005. After one year period of construction inspected and reviewed by experts, the laboratory was finally approved in 2006 by Ministry of Science and Technology of China and formally named as The State Key Laboratory of Cancer Biology which became the first one to commence operation among the same batch of constructing laboratories. Prof. Shujun Cheng and Xishan Hao are the present director and associate director of academic committee of CBSKL respectively. Prof Daiming Fan is the director of CBSKL. All of them are academicians of Chinese Academy of Engineering.
Malignant tumour is still a serious threat to human health. The major tasks of current cancer biology research are to identify the characteristics and patterns of cancer biology , especially molecular events and underlying regulatory mechanisms accounting for tumour formation and development，and to design ideal diagnostic techniques as well as effective treatments. CBSKL mainly focuses on two of the most common tumours of the gastrointestinal tract in human beings, i.e. gastric carcinoma and hepatic cellular carcinoma. We applied ourselves to the following research scopes: (1) The identification and underlying network regulation of tumour associated molecules. (2) Establishment of molecular alerting system and early diagnosis tools of tumours. (3) The exploration and application of novel strategy in tumour bio-therapy. According to distinct research fields and corresponding scientific issues, Laboratory sets up 12 research units as follows: tumour multi-drug resistance, tumour proliferation and metastasis, tumour differentiation, tumour cell apoptosis, tumour angiogenesis and anti-angiogenesis therapy, molecular warning of tumour, tumour gene therapy, tumour vaccine, anti-tumour antibody engineering and affinity proteomics, biochips, tumour targeting therapy, bioinformatics.
With the development of Laboratory, the research work has made significant progress and achievements as follows: (1) We systematically studied the novel molecules and underlying mechanisms involved in the development of tumour multi-step progression and identified 5 groups of molecules associated with tumour apoptosis, proliferation, drug resistance etc, and tried to find the key molecules related to gastric cancer progression, on the basis of which we put forward “III levels & IV steps” serial aleting strategy, including ” Helicobacter Pylori eradication, Non-steroidal anti-inflammatory drug application, MG7Ag monitoring, MDR reversal”, which enabled us to win the Class I prize of National Science and Technology Progress Award. (2) We have developed anti-HAb18G engineering antibodies against liver cancer. Licartin (Iodine [131I] conjugated HAb18) is a new drug and we have 100% of intellectual property right. We have verified the function of this drug on therapy against the recurrence and migration of liver cancer and acquired the class I national new medicine certificates of Biological Products and a production catalogued number. (3) We have successfully got a targeted pro-apoptotic secretory protein with high-efficiency and low-immunogenicity, and verified its specific function against HER2-positive tumour cells and have accomplished the preclinical study. (4) We have developed liver cancer -targeted immunological gene therapy reagent in which SEA/CD80 were co-expressed as well as a gene engineering nano-vaccine based on super-antigen. The preclinical study of these two products above has been accomplished and entered pilot scale production. (5) We have invented composite biochips and developed the diagnostic biochip for gastric cancer, which has also entered the clinical trial. (6) We have systematically studied and clarified the regulatory effects of NDRG2 and Notch signal pathway on tumorigenesis and tumour angiogenesis.
With these significant research achievements and advancements, we have won the Class I and Class II prizes of National Science and Technology Progress Awards, one Technology Award of Chinese Pharmaceutical Association and dozens of provincial science and technology awards. We have acquired two class I national new medicine certificates of Biological Products and one class I national new medicine certificate of test reagent. We have got nearly one hundred items of invention patents. As the first or corresponding author we have more than two hundreds international publications that mainly presented on well recognized journals such as Nature Clinical Practice Oncology, Lancet, Hepatology etc which have achieved sound economical and social effects.
The staff of Laboratory is consisted of a group of academic leading scientists with outstanding contributions in domestic associated research fields. Currently, 85% of the stable people have Ph.D degree and 35 of them have experience of oversea training in U.S.A, England or Japan etc. Two are Academicians of Chinese Academy of Engineering and four have been entitled Professorship of Chang jiang Scholars Program. Five have been granted national distinguished youth funds. Two became the chief expert of the State Key Basic Research Grant of China (“973” program) and one is the subject expert of High-Tech R&D Program Grant (“863” program). Two professors serve as standing committee in international academic organizations. The research group under the leadership of Prof. Daiming Fan was the first Innovative Research Group of National Natural Science Foundation of China. The two research groups of Prof. Angang Yang and Zhinan Chen were approved as Innovative Group of Ministry of Education in 2005 and 2009 respectively.
Since CBSKL was open to the outside in 2006, three batches of Opening Projects have been approved. Laboratory has attracted many domestic and foreign scholars to do research here. Laboratory has established stable academic collaborations and exchanges with a number of famous universities or institutes in countries such as the USA, England, Canada and Switzerland. Laboratory has hosted and undertaken 8 international, 2 bilateral and 21 national academic conferences. 22 persons have been invited as chairmans and co-chairmans in the main venue or chairmans in the branch venue. The director of Laboratory，Prof. Daiming Fan，is the council member of Asia-Pacific Association of Gastroenterology and Chairman of Internal Affair Committee, and elected as congress President of Asia-Pacific Digestive Week and World Congress of Gastroenterology in 2013.
With the powerful support of the Fourth Military Medical University and PLA General Logistics Department and Ministry of Health, CBSKL strives to construct the laboratory and make it become a cancer biology research base yielding high-level achievements, a cradle in which high quality researchers are cultivated, an exchange centre to make comprehensive research collaborations both at home and abroad. And we are trying to make every effort to make great contributions to the economic construction and social development of our country.